A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.

In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.

This is according to the largest-ever analysis of the treatment cascade among people tested for hep C.

Whether such recurrence is less likely after interferon treatment remains the source of some controversy in the hep C research community.

Preliminary results from an ongoing trial found that half of the participants could take less than 12 weeks of a cure regimen.

Liver fat may be a driver of increased cancer risk associated with obesity.

A second immunotherapy option is now available for hepatocellular carcinoma.

Preterm delivery is defined as giving birth before 37 weeks of gestation.

Investigators have found biomarkers that might one day be used to help detect liver cancer during earlier stages.

Treating hep C lowers the risk.